Mesoblast Limited (ASX:MSB)


right-arrow Created with Sketch. 0.035 (2.25%)
MCAP $1.008B
Last trade 13.52pm 06/12/2021 20mins delayed

Latest Announcements

10.00am 06/12/2021MSBMesoblast Limited
09.55am 06/12/2021MSBMesoblast Limited
29/11/2021MSBMesoblast Limited
29/11/2021MSBMesoblast Limited
29/11/2021MSBMesoblast Limited
24/11/2021 Price SensitivePSMSBMesoblast Limited
24/11/2021MSBMesoblast Limited
24/11/2021 Price SensitivePSMSBMesoblast Limited

Company Overview

Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

MSB in the news

Mesoblast (MSB) trades slightly higher on the ASX following the release of…
Mesoblast (MSB) refinances existing senior debt facility with new, roughly $124 million…
Mesoblast (MSB) spikes on the ASX today after announcing findings from a…
Mesoblast (MSB) tumbles on the ASX today after flagging a wider year-on-year…

Search Previous Announcements